menu
    • menu

    Company profile for Lindis Biotech

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Lindis Biotech is a clinical stage bio-pharmaceutical company that is committed to the development of Triomab® antibodies – a new class of T-cell engaging bispecific antibodies, empowering the immune system to turn malignant cancers into manageable and possibly curable diseases. We combine scientific & pharmaceutical experience. We engage for safe and efficacious biomedical products.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Lindis BiotechGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Am Klopferspitz 19 82152 Martinsried, Munich
    Telephone
    Telephone
    +49 89 45239600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.lindisbiotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharmanovia Launches Korjuny in Germany for Malignant Tumors
    Pharmanovia Launches Korjuny in Germany for Malignant Tumors

    15 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-15/pharmanovia-announces-launch-of-korjuny-catumaxomab-in-germany-a-first-in-class-treatment-for-mal

    PHARMIWEB
    15 Dec 2025
    Share Share
    Celonic, LINDIS Biotech Ink Pact for Catumaxomab Production
    Celonic, LINDIS Biotech Ink Pact for Catumaxomab Production

    19 Feb 2025

    // CONTRACTPHARMA

    https://www.contractpharma.com/breaking-news/celonic-group-lindis-biotech-sign-manufacturing-service-agreement-for-catumaxomab/

    CONTRACTPHARMA
    19 Feb 2025
    Share Share
    Lindis Biotech & Pharmanovia Get EU Approval in Malignant Ascites
    Lindis Biotech & Pharmanovia Get EU Approval in Malignant Ascites

    13 Feb 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/lindis-biotech-and-pharmanovia-announce-european-marketing-authorizati-984539

    ACCESSWIRE
    13 Feb 2025
    Share Share
    Lindis Licenses Catumaxomab to Pharmanovia for Commercialization
    Lindis Licenses Catumaxomab to Pharmanovia for Commercialization

    19 Nov 2024

    // ACCESSWIRE

    https://www.accesswire.com/944365/lindis-biotech-signs-licensing-agreement-with-pharmanovia-for-the-commercialization-of-catumaxomab

    ACCESSWIRE
    19 Nov 2024
    Share Share
    Lindis Biotech Receives Positive CHMP Opinion For Korjuny® in EU
    Lindis Biotech Receives Positive CHMP Opinion For Korjuny® in EU

    21 Oct 2024

    // ACCESSWIRE

    https://www.accesswire.com/933436/lindis-biotech-receives-positive-chmp-opinion-for-korjuny-catumaxomab-in-the-european-union

    ACCESSWIRE
    21 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search